FDA grants fast track status to Dara cancer drug
The company has previously released positive results from a Phase II (DTCL100) trial evaluating KRN5500, which demonstrated reduction of pain and safety and was superior to placebo. Based
Biointron Biological has launched RushData, a new platform to support the process of antibody discovery for pharmaceutical and biotechnology companies employing AI and machine learning (ML).